BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates With ORLADEYO (Berotralstat)
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
BioCryst to Report Third Quarter 2024 Financial Results on November 4
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking
BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?